

Santhanam Sundar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7588283/publications.pdf>

Version: 2024-02-01

105
papers

4,908
citations

331538

21
h-index

91828

69
g-index

107
all docs

107
docs citations

107
times ranked

7037
citing authors

#	ARTICLE	IF	CITATIONS
1	Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. <i>Lancet, The</i> , 2016, 387, 1163-1177.	6.3	1,570
2	Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , 2014, 15, 700-712.	5.1	1,280
3	Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3â€“pT4 or N+ MO urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2015, 16, 76-86.	5.1	323
4	Platinum-based chemotherapy in metastatic breast cancer: current status. <i>Cancer Treatment Reviews</i> , 2004, 30, 53-81.	3.4	184
5	Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991. <i>Journal of Clinical Oncology</i> , 2016, 34, 1748-1756.	0.8	182
6	Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. <i>Lancet, The</i> , 2022, 399, 447-460.	6.3	173
7	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2017, 390, 2266-2277.	6.3	153
8	Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. <i>European Urology</i> , 2020, 78, 822-830.	0.9	99
9	A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer. <i>European Urology</i> , 2016, 69, 450-456.	0.9	80
10	Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991. <i>European Journal of Cancer</i> , 2009, 45, 2825-2834.	1.3	74
11	Radiotherapy to patients with artificial cardiac pacemakers. <i>Cancer Treatment Reviews</i> , 2005, 31, 474-486.	3.4	69
12	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , 2020, 21, 105-120.	5.1	61
13	Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 904-910.	0.4	52
14	A novel case based reasoning approach to radiotherapy planning. <i>Expert Systems With Applications</i> , 2011, 38, 10759-10769.	4.4	50
15	Information needs of Asian and White British cancer patients and their families in Leicestershire: a cross-sectional survey. <i>British Journal of Cancer</i> , 2004, 90, 1474-1478.	2.9	39
16	Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the <sc>UK</sc> Early Access Programme (EAP) (<sc>NCT</sc>O1254279). <i>BJU International</i> , 2015, 116, 880-887.	1.3	36
17	Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate. <i>BMJ Case Reports</i> , 2012, 2012, bcr1120115238-bcr1120115238.	0.2	32
18	Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy. <i>Gynecologic Oncology</i> , 2004, 94, 502-508.	0.6	31

#	ARTICLE	IF	CITATIONS
19	A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv197.	3.0	29
20	Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 1770-1777.	0.8	27
21	Impact of neutropenia on delivering planned chemotherapy for solid tumours. <i>European Journal of Cancer Care</i> , 2007, 17, 070921230504001-???	0.7	26
22	Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease. <i>Journal of Clinical Oncology</i> , 2021, 39, 3022-3033.	0.8	24
23	A self-adaptive case-based reasoning system for dose planning in prostate cancer radiotherapy. <i>Medical Physics</i> , 2011, 38, 6528-6538.	1.6	20
24	Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. <i>European Urology Oncology</i> , 2018, 1, 449-458.	2.6	19
25	Anaemia is Associated with Poor Overall Survival but not with Inferior Local Control in Patients with Muscle Invasive Bladder Carcinoma Treated by Radical External Beam Radiotherapy. A Retrospective Study. <i>Clinical Oncology</i> , 2006, 18, 728-734.	0.6	16
26	Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy. <i>BMJ Case Reports</i> , 2014, 2014, bcr2013202861-bcr2013202861.	0.2	16
27	Best practice in primary care pathology: review 4. <i>Journal of Clinical Pathology</i> , 2006, 59, 893-902.	1.0	15
28	Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate. <i>British Journal of Cancer</i> , 2012, 106, 1464-1465.	2.9	15
29	Reversibility of liver failure secondary to metastatic breast cancer by vinorelbine and cisplatin chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 367-370.	1.1	14
30	Epidermal Growth Factor Receptor Status Predicts Local Response to Radical Radiotherapy in Muscle-invasive Bladder Cancer. <i>Clinical Oncology</i> , 2006, 18, 702-709.	0.6	14
31	Evaluation of the status of tuberculosis as part of the clinical case definition of AIDS in India. <i>Postgraduate Medical Journal</i> , 2005, 81, 404-408.	0.9	13
32	Prolonged Hypocalcemia After Zoledronic Acid in a Patient With Metastatic Prostate Carcinoma: Did Zoledronic Acid Trigger Osteoblastic Activity and Avid Calcium Uptake?. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 50-53.	0.9	12
33	A phase II/III, double-blind, randomized trial comparing maintenance lapatinib versus placebo after first line chemotherapy in HER1/2 positive metastatic bladder cancer patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4505-4505.	0.8	12
34	Tolerance of Pelvic Organs to Radiation Treatment for Carcinoma of Cervix. <i>Clinical Oncology</i> , 2003, 15, 240-247.	0.6	11
35	Platinum-based Chemotherapy in Metastatic Breast Cancer: The Leicester (UK) Experience. <i>Clinical Oncology</i> , 2005, 17, 249-257.	0.6	11
36	Re-induction of hormone sensitivity to diethylstilboestrol in androgen refractory prostate cancer patients following chemotherapy. <i>British Journal of Cancer</i> , 2008, 98, 238-239.	2.9	10

#	ARTICLE	IF	CITATIONS
37	The Return of the Snake Oil Salesmen: TheÂSequel. International Journal of Radiation Oncology Biology Physics, 2012, 84, 571.	0.4	10
38	Diagnostic Radiology for Radiotherapist: the Case for Structured Training in Cross-Sectional Imaging (CT and MRI). Clinical Oncology, 2002, 14, 413-414.	0.6	8
39	Geographical tongue induced by axitinib. BMJ Case Reports, 2015, 2015, bcr2015211318.	0.2	8
40	Misconceptions about "do-not-resuscitate (DNR)" orders in the era of social media. Resuscitation, 2015, 86, e3.	1.3	8
41	Evolution of the Treatment Paradigm for Patients with Metastatic Castration-Resistant Prostate Cancer. Advances in Therapy, 2013, 30, 1041-1066.	1.3	7
42	Neutrophilâ€lymphocyte ratio is prognostic but not predictive of response to Abiraterone in metastatic castration-resistant prostate cancer. JRSM Open, 2015, 6, 205427041561133.	0.2	7
43	Degree of Rectal Distension Seen on Prostate Radiotherapy Planning CT Scan Is Not a Negative Prognostic Factor in the Modern Era of Image-Guided Radiotherapy. Oncology, 2016, 90, 51-56.	0.9	6
44	RE: Denosumab for Patients With Persistent or Relapsed Hypercalcemia of Malignancy Despite Recent Bisphosphonate Treatment. Journal of the National Cancer Institute, 2015, 107, dju509-dju509.	3.0	5
45	New law on consent will overload seriously ill patients. BMJ, The, 2015, 350, h1787-h1787.	3.0	5
46	PLUTO: A randomised phase II study of pazopanib versus paclitaxel in relapsed urothelial tumours.. Journal of Clinical Oncology, 2016, 34, 430-430.	0.8	5
47	A Knowledge-Light Nonlinear Case-Based Reasoning Approach to Radiotherapy Planning. , 2009, , .		4
48	Prognosis of early stage small cell bladder cancer is not always dismal. ESMO Open, 2019, 4, e000559.	2.0	4
49	Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Interim safety and quality-of-life (QOL) data from the U.K. early access program (NCT01254279).. Journal of Clinical Oncology, 2012, 30, 44-44.	0.8	4
50	Cholestatic jaundice and pseudomembranous colitis following combination therapy with doxorubicin and docetaxel. Anti-Cancer Drugs, 2003, 14, 327-329.	0.7	3
51	Age Does Not Influence Acute Toxicity During Radiotherapy Dose Escalation for Prostate Cancer. Clinical Oncology, 2006, 18, 506-507.	0.6	3
52	A randomized phase II study of AZ2014 versus everolimus in patients with VEGF refractory metastatic clear cell renal cancer (mRCC).. Journal of Clinical Oncology, 2015, 33, 409-409.	0.8	3
53	Management of endocrine resistant breast cancer. The Journal of the British Menopause Society, 2004, 10, 16-23.	1.3	2
54	International register of trial acronyms. Lancet, The, 2004, 363, 171.	6.3	2

#	ARTICLE	IF	CITATIONS
55	Sugar-free medicines are counterproductive. <i>British Dental Journal</i> , 2012, 213, 207-208.	0.3	2
56	Prostate radiation in non-metastatic castrate refractory prostate cancer provides an interesting insight into biology of prostate cancer. <i>Radiation Oncology</i> , 2012, 7, 43.	1.2	2
57	Benchmarking 30 Day Mortality After Palliative Chemotherapy for Solid Tumours. <i>Clinical Oncology</i> , 2014, 26, 236.	0.6	2
58	Cancer patients' anxiety. <i>Lancet</i> , The, 2003, 361, 1746-1747.	6.3	1
59	Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to Achieve Castration Levels in Patients Using Leuprolide Acetate in Locally Advanced Prostate Cancer. <i>Eur Urol</i> 2006;49:54â€“8. <i>European Urology</i> , 2007, 51, 1146.	0.9	1
60	Re: Arnulf Stenzl, Nigel C. Cowan, Maria De Santis, et al. Treatment of Muscle-Invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines. <i>Eur Urol</i> 2011;59:1009â€“18. <i>European Urology</i> , 2011, 60, e51.	0.9	1
61	Cabazitaxel Rechallenge at Prostate-Specific Antigen Relapse After Previous Cabazitaxel and Docetaxel Chemotherapy: Case Report. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 207-209.	0.9	1
62	Some forms of knowledge are more equal than others. <i>BMJ</i> , The, 2012, 345, e7429-e7429.	3.0	1
63	Salvage radiotherapy after high intensity focused ultrasound for prostate cancer. <i>BMJ Case Reports</i> , 2012, 2012, bcr0320126127-bcr0320126127.	0.2	1
64	715 CABAZITAXEL FOR METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC): FINAL QUALITY OF LIFE (QOL) RESULTS WITH SAFETY DATA FROM THE UNITED KINGDOM (UK) EARLY ACCESS PROGRAMME (EAP) (NCT01254279). <i>Journal of Urology</i> , 2013, 189, .	0.2	1
65	"Saatchi bill": legal hurdles and clinical irrelevance. <i>BMJ</i> , The, 2014, 348, g3146-g3146.	3.0	1
66	Milk and mortality: the potential effects of modern milk production. <i>BMJ</i> , The, 2014, 349, g7006-g7006.	3.0	1
67	Clinical surgical trials need to be encouraged. <i>BMJ</i> , The, 2015, 350, h282-h282.	3.0	1
68	Resuscitation is futile in terminally ill patients. <i>BMJ</i> , The, 2016, 352, i598.	3.0	1
69	Should Elderly Prostate Cancer Patients with Comorbidity be Spared from Prostate Radiation Dose Escalation?. <i>Clinical Oncology</i> , 2016, 28, 227-228.	0.6	1
70	Public health needs to go back to basics, not rely on nudge theory. <i>BMJ</i> , The, 2021, 373, n1153.	3.0	1
71	Adjuvant Hormone Therapy After Prostate Radiation: Is This Data Torture?. <i>Journal of Clinical Oncology</i> , 2021, 39, 2314-2315.	0.8	1
72	Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Final quality-of-life (QOL) results with safety data from the United Kingdom (UK) Early Access Programme (EAP) (NCT01254279).. <i>Journal of Clinical Oncology</i> , 2013, 31, 91-91.	0.8	1

#	ARTICLE	IF	CITATIONS
73	Male Cancer Patients' Attitudes towards Female Health Professionals during Urological Consultations. <i>Clinical Oncology</i> , 2006, 18, 572-573.	0.6	0
74	Utility of Regular Serum Biochemistry and Midstream Urine Cultures in Men undergoing Three-dimensional Conformal Pelvic Radiotherapy for Prostate Cancer. <i>Clinical Oncology</i> , 2007, 19, 162.	0.6	0
75	The Clinical Usefulness of DNA Aneuploidy in Borderline Ovarian Tumours. <i>Onkologie</i> , 2012, 35, 607-607.	1.1	0
76	Claims about NHS deficiencies without robust data undermine trust. <i>BMJ, The</i> , 2013, 347, f6158-f6158.	3.0	0
77	The law of unintended consequences. <i>Journal of the Royal Society of Medicine</i> , 2013, 106, 303-303.	1.1	0
78	Patients with cancer say yes to palliative chemotherapy. <i>BMJ, The</i> , 2013, 347, f4647-f4647.	3.0	0
79	Re: Michael T. Schweizer, Xian C. Zhou, Hao Wang, et al. The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer. <i>Eur Urol</i> 2014;66:646-52. <i>European Urology</i> , 2015, 67, e113-e114.	0.9	0
80	Understanding cardiopulmonary resuscitation. <i>Journal of Pediatrics</i> , 2017, 190, 291-292.	0.9	0
81	Categorising severity of disease is inevitable and essential in routine medical practice. <i>BMJ: British Medical Journal</i> , 2018, 361, k2556.	2.4	0
82	Late cancer diagnoses: biology triumphs clinical acumen. <i>BMJ: British Medical Journal</i> , 2019, 366, l5155.	2.4	0
83	High sensitivity troponin assays: too much of a good thing. <i>BMJ: British Medical Journal</i> , 2019, 365, l1640.	2.4	0
84	Palliative care: relocation rather than rebranding is needed. <i>BMJ: British Medical Journal</i> , 2019, 365, l1641.	2.4	0
85	Renaming low risk cancers: honest engagement with patients is more important. <i>BMJ: British Medical Journal</i> , 2019, 364, l840.	2.4	0
86	Treating sepsis in dying patients is futile. <i>BMJ, The</i> , 2019, 367, l6706.	3.0	0
87	Banning free speech is counterproductive. <i>BMJ: British Medical Journal</i> , 2019, 366, l4626.	2.4	0
88	On emotions and clinical judgment. <i>BMJ, The</i> , 2020, 370, m3723.	3.0	0
89	In defence of hope. <i>BMJ, The</i> , 2020, 371, m3904.	3.0	0
90	Covid-19 risk assessment: a futile metaphorical strip search. <i>BMJ, The</i> , 2020, 370, m3251.	3.0	0

#	ARTICLE	IF	CITATIONS
91	Prostate cancer: trial data meet the real world. <i>BMJ, The</i> , 2020, 368, m519.	3.0	0
92	Call-out culture demands perfection from everyone except oneself. <i>BMJ, The</i> , 2020, 368, m158.	3.0	0
93	Interpreting test results: don't blame the tools. <i>BMJ, The</i> , 2020, 368, m1162.	3.0	0
94	Misconceptions about CPR distress patients at the end of life and bereaved people. <i>BMJ, The</i> , 2021, 373, n1060.	3.0	0
95	Re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. <i>Eur Urol</i> 2021;79:307-15. <i>European Urology</i> , 2021, 80, e49-e50.	0.9	0
96	Changing the implied consent model for investigations is not easy. <i>BMJ, The</i> , 2021, 374, n1940.	3.0	0
97	EORTC trial 22991: Results of a phase III study comparing 6 months of androgen suppression and irradiation versus irradiation alone for localized T1b-cT2aNOMO prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 22-22.	0.8	0
98	Concurrent boost technique in prostate IMRT and accuracy of planning target volume (PTV) at the periphery.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16615-e16615.	0.8	0
99	Tolerability and efficacy of lower dose of cabazitaxel (20mg/m ²) in castration-refractory prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2016, 34, e16545-e16545.	0.8	0
100	A confirmatory survey regarding public misconception about cardiopulmonary resuscitation (CPR) in advanced cancer patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21507-e21507.	0.8	0
101	Biomarker to cost-effectively harness the technical prowess of palliative radiation: Neutrophil lymphocyte ratio (NLR) and overall survival following palliative radiotherapy in an unselected real-world population of all tumor sites.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10111-10111.	0.8	0
102	Validation of a testosterone-deficiency symptoms rating-scale in prostate cancer patients treated with androgen deprivation therapy and radiotherapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 63-63.	0.8	0
103	Effect of pre-treatment anxiety and depression on long term survival of prostate cancer patients treated radically with radiation and hormone therapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, e23087-e23087.	0.8	0
104	Plain English is neither simple nor easy. <i>BMJ, The</i> , 2020, 368, m949.	3.0	0
105	Awareness of normal risk is not normal. <i>BMJ, The</i> , 2020, 371, m4121.	3.0	0